

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)



Complete if Known

Application Number 09/234532

Filing Date January 21, 1999

First Named Inventor Sapse, Alfred

Group Art Unit 1623

Examiner Name Unknown

Sheet 1 of 1

Attorney Docket No: 1941.006US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
<i>AO</i>	US-4,956,391	09/11/1990	Sapse, A	514	810	08/17/1988

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²
--------------------	---------------------	------------------	---	-------	----------	----------------

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁴
<i>AO</i>		BHANSALI, A, et al., "A preliminary report on basal & stimulated plasma cortisol in patients with acquired immunodeficiency syndrome," <u>Indian J Med Res.</u> , 112, (Nov. 2000), 173-7	
<i>AO</i>		CHRISTEFF, N, et al., "Changes in cortisol/DHEA ratio in HIV-infected men are related to immunological and metabolic perturbations leading to malnutrition and lipodystrophy," <u>Ann N Y Acad Sci.</u> , 917, (2000), 962-70	
<i>AO</i>		CORLEY, P A., "Acquired immune deficiency syndrome: the glucocorticoid solution," <u>Med Hypotheses</u> , 47 (1), (July 1996), 49-54	
<i>AO</i>		XU, J, et al., "Inhibition of adrenal cortical steroid formation by procaine is mediated by reduction of the cAMP-induced 3-hydroxy-3-methylglutaryl-coenzyme A reductase messenger ribonucleic acid levels," <u>J Pharmacol Exp Ther.</u> , 307(3), Epub 2003 Oct 14., (Dec. 2003), 1148-57	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached